113 related articles for article (PubMed ID: 22443134)
1. Metastatic melanoma: the new era of targeted therapy.
Guida M; Pisconti S; Colucci G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S61-70. PubMed ID: 22443134
[TBL] [Abstract][Full Text] [Related]
2. New drugs in melanoma: it's a whole new world.
Eggermont AM; Robert C
Eur J Cancer; 2011 Sep; 47(14):2150-7. PubMed ID: 21802280
[TBL] [Abstract][Full Text] [Related]
3. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
[TBL] [Abstract][Full Text] [Related]
4. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Aug; 16(8):811-26. PubMed ID: 27403706
[TBL] [Abstract][Full Text] [Related]
6. [BRAF mutation testing for the choice of melanoma treatment].
Imianitov EN
Arkh Patol; 2012; 74(5):65-71. PubMed ID: 23342664
[TBL] [Abstract][Full Text] [Related]
7. Targeting metastatic melanoma.
Flaherty KT
Annu Rev Med; 2012; 63():171-83. PubMed ID: 22034865
[TBL] [Abstract][Full Text] [Related]
8. New therapeutical strategies in the treatment of metastatic disease.
Julia F; Thomas L; Dalle S
Dermatol Ther; 2012; 25(5):452-7. PubMed ID: 23046024
[TBL] [Abstract][Full Text] [Related]
9. BRAF, a target in melanoma: implications for solid tumor drug development.
Flaherty KT; McArthur G
Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
[TBL] [Abstract][Full Text] [Related]
10. [Melanoma: a new therapeutic era].
Berthod G; Homicsko K; Bouchaab H; Matter M; Cerottini JP; Guggisberg D; Speiser D; Leyvraz S; Michielin O
Rev Med Suisse; 2011 May; 7(296):1126-30. PubMed ID: 21721201
[TBL] [Abstract][Full Text] [Related]
11. Novel treatment strategies for malignant melanoma: a new beginning?
Kasper B; D'Hondt V; Vereecken P; Awada A
Crit Rev Oncol Hematol; 2007 Apr; 62(1):16-22. PubMed ID: 17208006
[TBL] [Abstract][Full Text] [Related]
12. [Selective blockade of the mutated BRAF leads to a survival benefit in patients with metastatic melanoma].
Schadendorf D
J Dtsch Dermatol Ges; 2011 Apr; 9(4):340. PubMed ID: 21439018
[No Abstract] [Full Text] [Related]
13. Melanoma: understanding relevant molecular pathways as well as available and emerging therapies.
McKibbin T
Am J Manag Care; 2015 Sep; 21(10 Suppl):S224-33. PubMed ID: 26619296
[TBL] [Abstract][Full Text] [Related]
14. Metastatic melanoma: optimizing outcomes by managing dermatologic toxicities associated with novel therapies.
Claveau J; Ho V; Petrella T
Skin Therapy Lett; 2014; 19(2):1-4. PubMed ID: 24740745
[TBL] [Abstract][Full Text] [Related]
15. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Kirkwood JM; Moschos S; Wang W
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
[TBL] [Abstract][Full Text] [Related]
16. New drug targets in metastatic melanoma.
Homet B; Ribas A
J Pathol; 2014 Jan; 232(2):134-41. PubMed ID: 24027077
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.
Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF
J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy for advanced melanoma: fulfilling the promise.
Gogas H; Polyzos A; Kirkwood J
Cancer Treat Rev; 2013 Dec; 39(8):879-85. PubMed ID: 23725878
[TBL] [Abstract][Full Text] [Related]
19. Melanoma: from darkness to promise.
Gasent Blesa JM; Grande Pulido E; Alberola Candel V; Provencio Pulla M
Am J Clin Oncol; 2011 Apr; 34(2):179-87. PubMed ID: 20498590
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous melanoma: available therapy for metastatic disease.
Tarhini AA; Agarwala SS
Dermatol Ther; 2006; 19(1):19-25. PubMed ID: 16405566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
